Abstracts 1

1
EUROGIN 2016 ABSTRACTS
Part I – Main Conference Program
MTC MAIN TRAINING COURSES…………………………...P.2
STC SATELLITE TRAINING COURSES……………………P.36
MSS MAIN SCIENTIFIC SESSION ………………………….P.59
SSIM SCIENTIFIC SESSIONS ON IMMUNOLOGY AND
IMMUNOTHERAPEUTICS ………………………………….P.105
ES EDUCATIONAL SESSION………………………………P.134
HN HEAD AND NECK SESSIONS…………………………P.136
CS CLINICAL SESSIONS.…………………………………..P.200
WACC WACC SESSIONS…………………………………..P.238
SS SCIENTIFIC SESSIONS…………………………………P.287
GS GERMAN LANGUAGE SESSIONS……………………P.409

2
MTC 01-01
The burden of HPV associated cancers in men and women
G. Clifford, S. Franceschi, M. Plummer, C. De Martel
IARC (France)
Background / Objectives
The contribution of infections to the global burden of cancer has been assessed periodically, and in
the last assessment for 2008, it was estimated that 610 000 (4.8%) of all cancers worldwide were
attributable to HPV (de Martel 2012). We have since updated these statistics for the year 2012 using
estimates of global cancer incidence from Globocan 2012, as well as improved estimates of
population attributable fractions (PAF) for infectious agents derived from a recent literature
review, including a new attribution of a small proportion of oral cavity and larynx cancers to HPV.
Methods
The fractions of all cancers attributable to HPV in women and men in 2012 were compared
worldwide by 8 geographical regions, and according to the Human Development Index (HDI).
Separate estimates are presented for countries that have a large population or a distinct level of
economic development compared to other countries in the region (China, India, Japan, South Korea,
Australia and New Zealand). The PAF for HPV was estimated to be 100% for cervical cancer, 88% for
anal cancer, 78% for vaginal cancer, 51% for penile cancer, 25% for vulvar cancer, 4% of oral cavity
and larynx cancer and a variable proportion of oropharynx depending on region (from 15-69%
depending on world region).
Results
Of newly diagnosed cancer cases worldwide in 2012, 640,000 were estimated to be attributable to
HPV, of which 570,000 were diagnosed in women, and 66,000 in men. These included 270,000,
280,000 and 90,000 cases diagnosed in age groups <50, 50 to 69 years and 70+ years, respectively.
Among women, the large majority of the burden was contributed by cervical cancer (530,000),

3
followed by Anus (18,000), Vagina (12,000), Vulva (8,500), Oropharynx (5,500), Oral cavity (3,000)
and Larynx (860) cancer. For men, the contribution was from Oropharynx (24,000), Anus (17,000),
Penis (13,000), Oral cavity (5,600) and Larynx (6,400). In low-HDI countries, HPV-related cancers
constitute half of all infection related cancers, but the proportion of all infection-related that are
caused by HPV decreases with HDI level, mainly due to the screening and treatment of cervical
precancerous lesions.
Conclusion
In every world region, the burden of HPV-related cancer is driven by cervical cancer incidence.
Differences in the burden of HPV-related cancer between the two sexes in any world region thus
depends mainly on: 1) the effectiveness of cervical screening programs; and, to a lesser extent, 2) the
fraction of oropharyngeal cancer attributable to HPV.
References
[de Martel C, et al. Lancet Oncol;13(6):607-15 (2012)].

4
MTC 01-02
The state of the art of HPV epidemiology, cervical vs oral
S. De Sanjose
Catalan Institute of Oncology (Spain)
Background / Objectives
Human Papilloma Virus is one of the most common viral agents infecting skin and mucoses in
humans. It is now well established that persistent HPV infection with some specific HPV types, the so
called high-risk types, leads to a deregulation of viral gene expression and altered cell functions
including cell proliferation, poor DNA repair, and accumulation of genetic changes. All these changes
are linked to anogenital cancers including cervix, vagina, vulva, anal canal, penis, and head and neck
cancers, particularly oropharyngeal. The HPV aetiological contribution differs in each location
reflecting different natural history and different tropism. HPV contributes to over 530,000 new
cervical cancer cases and over 80,000 of other related sites every year worldwide. Geographical and
social differences in incidence and mortality are prominent particularly for cervical cancer as its
burden is highly related to screening and treatment facilities.
Methods
A literature search within Pubmed on HPV and epidemiology of Cervical cancer and HNSCC has been
carried out.
Results
Over the last decade, increasing amount of information on the role of HPV in head and neck
squamous cell carcinomas (HNSCC) has been amassed. While HPV persistent infection is the
necessary cause of the vast majority of cervical cancers this is not the case for cancers of the vulva,
penile and HNSCC. Nowadays, it is widely accepted that HPV-positive HNSCC differ significantly from
HPV-negative HNSCC, mainly caused by tobacco and alcohol, on the genetical, molecular,
epidemiological and clinical level. The HPV involvement in the carcinogenic process may derive in a
major impact in the clinical management of HNSCC patients. This is distinctive from the accepted
treatment regimes in other HPV related cancers in which HPV involvement has not been yet
associated to differential regimes.

5
Conclusion
Prevention strategies are moving towards incorporating HPV testing in screening practices and HPV
vaccination as primary prevention of cervical cancer and other ano-genital cancer. However, the
impact of secondary preventive measures in HNSCH HPV positive cases need to be developed and
evaluated. It is expected that prophylactic vaccines could have an impact in HNSCC.